The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised rilzabrutinib, a new treatment option for adults living with immune thrombocytopenia (ITP). This approval is specifically for patients whose condition has not responded sufficiently to other available therapies, offering a new avenue for managing this challenging autoimmune disorder.
ITP is a rare bleeding disorder where the immune system mistakenly attacks and destroys platelets, the blood cells essential for clotting. This leads to low platelet counts, increasing the risk of bruising, bleeding, and in severe cases, internal haemorrhage. While current treatments aim to increase platelet counts or suppress the immune system, a significant proportion of patients do not achieve or maintain a satisfactory response, leaving them with ongoing symptoms and a reduced quality of life.
The authorisation of rilzabrutinib by the MHRA signifies a potential advancement in the treatment landscape for these difficult-to-treat patients. As with all newly approved medicines, the MHRA has stated that it will maintain close surveillance over the safety and effectiveness of rilzabrutinib. This ongoing monitoring is a standard procedure to ensure that the drug continues to meet regulatory standards and that any potential side effects are identified and assessed promptly.
For patients and clinicians, the availability of a new treatment option can be particularly impactful. According to NHS data, ITP affects approximately 3-5 per 100,000 adults each year, with varying degrees of severity. For those who experience persistent or recurrent low platelet counts despite conventional therapies like corticosteroids, immunoglobulins, or thrombopoietin receptor agonists, new mechanisms of action can be crucial in achieving disease control and improving patient outcomes.
While the MHRA's authorisation is a significant step, the next stage will involve assessment by bodies such as the National Institute for Health and Care Excellence (NICE) to determine its cost-effectiveness and suitability for routine use within the NHS. This process ensures that new treatments provide value for money and are integrated appropriately into clinical pathways across the UK.
Patients experiencing symptoms of ITP or concerns about their current treatment should always consult their GP or specialist for personalised medical advice. For urgent medical concerns, individuals are advised to call NHS 111.
Source: MHRA